Immunic Inc chief medical officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) with Proactive's Stephen Gunnion to mark MS Awareness Week in the UK. Dr Muehler described MS as a common autoimmune disease affecting around 4 million people globally, predominantly women diagnosed between ages 25 and 35. He detailed the two primary forms of MS: relapsing-remitting MS, experienced by approximately 80% of patients and characterized by unpredictable relapses, and primary progressive MS, which gradually worsens without relapses. Dr Muehler also outlined the symptoms MS patients endure daily, such as debilitating fatigue and cognitive issues affecting their quality of life. During the interview, he focused on Immunic Inc's ongoing clinical trials for vidofludimus calcium, designed to address these symptoms. This drug exhibits anti-inflammatory, antiviral, and neuroprotective effects, potentially providing a new dimension in MS treatment. Dr Muehler flagged upcoming trial results for Immunic's main programs in April 2025, with further significant updates expected in 2026. #multiplesclerosisawareness #ImmunicInc, #MSAwareness, #AutoimmuneDisease, #MedicalResearch, #ClinicalTrials, #Healthcare, #Neurology, #WomenInMedicine, #MedicalInnovation, #PatientCare, #QualityOfLife, #AutoimmuneAwareness, #MSResearch, #NeurologicalDisorders, #MedicalScience, #HealthAndWellness, #DiseaseAwareness, #ChronicIllness, #MedicalCommunity #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews